The minimize in paclitaxel CL observed from the presence of zosuquidar brought about a rise in some time which the plasma paclitaxel focus continues to be higher than 0.one mol L?one, which is understood to be a marker of equally toxicity (neutropenia) and efficacy [1]. Even though the impact of zosuquidar about the toxicity of the clinically appli